Novartis Keeps Fighting for Neupogen Biosimilar

Jun 04, 2015


Novartis' Sandoz unit asked a U.S. appeals court to lift a preliminary injunction barring it from selling its biosimilar Zarxio, a cheaper version of Amgen's cancer blockbuster, Neupogen.

Last month, the U.S. Court of Appeals for the Federal Circuit granted a preliminary injunction barring the sale of Zarxio while the two companies worked through a patent lawsuit.

A panel will decide whether Sandoz made appropriate disclosures to Amgen that it planned to produce a copy of Neupogen -- as the law requires. Amgen argues Sandoz failed to follow regulations about how notice is to be given regarding the launch of a biosimilar.

Read the Reuters article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments